Pumping Iron: How Hospitalist Should Manage Iron Deficiency Anemia-Slides

Slides
Pdf Summary
This document provides a comprehensive overview of iron-deficiency anemia (IDA) management for hospitalists, focusing on clinical presentation, diagnosis, and treatment strategies, including oral and intravenous (IV) iron supplementation.<br /><br />IDA commonly presents with symptoms like headache, fatigue, dyspnea on exertion, pica (notably pagophagia), and restless leg syndrome; however, many patients may be asymptomatic. Physical signs include pallor, alopecia, atrophic glossitis, and, rarely, koilonychia. The pathophysiology involves reduced iron availability leading to impaired hemoglobin synthesis.<br /><br />Diagnosis relies on iron studies—ferritin, serum iron, total iron-binding capacity (TIBC), and transferrin saturation (TSAT). Ferritin cutoffs vary: a level below 45 ng/mL suggests IDA in general, while higher ferritin levels with low TSAT indicate IDA in inflammatory states like chronic kidney disease (CKD), inflammatory bowel disease (IBD), or heart failure with reduced ejection fraction (HFrEF). Recent red blood cell transfusions can confound diagnosis by artificially elevating ferritin.<br /><br />Treatment options include oral iron (e.g., ferrous sulfate 325 mg daily or every other day) and IV iron. Oral iron absorption is limited (~10%), has gastrointestinal side effects, and may be poorly tolerated in conditions with malabsorption or severe anemia. IV iron is favored in patients with GI malabsorption, severe anemia (Hgb 6-7 g/dL, ferritin <10 ng/mL, TSAT <10%), certain comorbidities (e.g., HFrEF, ESRD on hemodialysis, malignancy/chemotherapy-induced anemia), or oral iron intolerance. IV iron formulations vary; dosing is calculated often using the Ganzoni equation.<br /><br />Risks of IV iron include infusion reactions (mostly non-IgE mediated pseudo-allergies), rare anaphylaxis (more with low molecular weight iron dextran), and hypophosphatemia (notably with ferric carboxymaltose). Infection risk from IV iron is not definitively increased if there is no active infection.<br /><br />A clinical case illustrates evaluating a 65-year-old man with Crohn’s disease, CKD, and severe microcytic anemia. Despite elevated ferritin (280 ng/mL), low TSAT (13.8%), and severe anemia warranted IV iron after transfusion. Endoscopic evaluation revealed a duodenal ulcer as the bleeding source, and the patient was treated accordingly.<br /><br />Follow-up includes rechecking hemoglobin, ferritin, and TSAT at six weeks, and pursuing further diagnostics (EGD, colonoscopy, H. pylori, celiac testing) to identify etiology. Decision algorithms emphasize tailoring therapy based on comorbidities, severity, tolerance, and infection status.<br /><br />In summary, effective IDA management in hospitalized patients requires careful interpretation of iron studies in clinical context, appropriate iron repletion route selection, monitoring for adverse effects, and investigation of underlying causes to guide targeted therapy.
Keywords
iron-deficiency anemia
IDA management
iron studies
ferritin levels
transferrin saturation
oral iron supplementation
intravenous iron therapy
iron absorption
anemia diagnosis
treatment strategies